PMDA Perspective on Use of Real‐World Data and Real‐World Evidence as an External Control: Recent Examples and Considerations
Open Access
- 3 January 2025
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (4) , 910-919
Abstract
Recent discussions about the utilization of real‐world data (RWD) and real‐world evidence (RWE) have been more focused on drug development for regulatory approval rather than during the post‐marketing stage. In Japan, RWD/RWE have been practically utilized as an external control for drug approval. Most cases were related to orphan diseases where the feasibility of conducting randomized controlled clinical trials was generally low. The utilization of RWD/RWE as an external control provides additional information that can support regulatory review for drug approval. However, many points should be taken into consideration through all stages of a study that is based on RWD/RWE, including planning, analysis, and interpretation. In this article, we present our recent review experience focusing on efficacy evaluations with an external control based on RWD/RWE that were submitted as a part of new drug applications in Japan, and we describe our regulatory consideration of the utilization of RWD/RWE for drug evaluation and approval. Points described in this article promote appropriate drug development based on RWD/RWE and facilitate a proper discussion about RWD/RWE utilization with PMDA. Further accumulation of regulatory experience in PMDA with RWD/RWE utilization will enhance our knowledge and contribute to better regulatory decision making for drug approvals based on RWD/RWE.Keywords
This publication has 37 references indexed in Scilit:
- External Controls to Study Treatment Effects in Rare Diseases: Challenges and Future DirectionsClinical Pharmacology & Therapeutics, 2024
- Use of quantitative bias analysis to evaluate single‐arm trials with real‐world data external controlsPharmacoepidemiology and Drug Safety, 2024
- SURF: A Screening Tool (for Sponsors) to Evaluate Whether Using Real‐World Data to Support an Effectiveness Claim in an FDA Application Has Regulatory FeasibilityClinical Pharmacology & Therapeutics, 2023
- Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA DecisionsClinical Pharmacology & Therapeutics, 2023
- Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in JapanClinical Pharmacology & Therapeutics, 2021
- The use of external controls: To what extent can it currently be recommended?Pharmaceutical Statistics, 2021
- Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for EuropeClinical Pharmacology & Therapeutics, 2019
- Evaluating the Use of Nonrandomized Real‐World Data Analyses for Regulatory Decision MakingClinical Pharmacology & Therapeutics, 2019
- Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in JapanInvestigational New Drugs, 2018
- Bayesian methods for the design and interpretation of clinical trials in very rare diseasesStatistics in Medicine, 2014